Apotex asks Canada to prefer its Lapelga

Apotex wants its Lapelga biosimilar rival to Amgen’s Neulasta (pegfilgrastim) reference brand to be Canada’s “preferred pegfilgrastim product”. With a proposed reimbursement list price of C$1,878.73 (US$1,457.01) per Lapelga (pegfilgrastim) 6mg/0.6ml pre-filled syringe, the biosimilar would offer a 25% discount to Neulasta, equivalent to a C$626.24 saving per syringe.